Thực trạng tăng huyết áp ở người 18 - 69 tuổi tại quận Thủ Đức, thành phố Hồ Chí Minh và hiệu quả can thiệp, 2018 - 2020 - 20

86. Danaei G., Finucane M. M., Lin J. K., et al. (2011). “National, regional, and global trén in systolic blood pressuere since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5·4 million participants”. The Lancet, 377(9765): 568-577.

87. Dewhurst M. J., Dewhurst F., Gray W. K., et al. (2013). “The high Prevalence of hypertension in rural-dwelling Tanzania older adults and the disparity between detection, treatment and control: a rule of sixths?”.

88. Dorobantu M., Darabont R., Ghiorghe S., et al. (2014). “Hypertension prevalence and control in Romania at a seven-year interval. Comparison of SEPHAR I and II surveys”. Journal of Hypertension, 32(1): 39.

89. Do H. T. P., Geleijnse J. M., L. M. B., et al. (2015). “National Prevalence and Associated Risk Factors of Hypertension and Prehypertension Among Vietnamese Adults”. Am J Hypertens, 28(1): 89-97.

90. Eide I. K., Torjescen P. A., et al. (2004). “Low – renin status in therapy – resistant hypertension: a clue to eficient treatment”. J Hyperten. 22: 2217–2226.

91. Falaschetti E., Mindell E., Mindell J., Knott C., et al. (2014). “Hypertension management in England: A Serial Cross-Sectional Study From 1994 to 2011”. The Lancet, 383(9932): 1912-1919.

92. Forouzanfar M. H., Alexander L., Anderson H. R., et al. (2015). “Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013”. The Lancet, 386(10010): 2287-2323.

93. Gandjour. A and Stock. S. (2007). “A national hypertension treatment program in Germany and its estimated impact on costs, life expec- tancy, and cost-effectiveness”. Health Policy, 83: 257-267.

94. Gaziano T.A., Bertra M., Tollman S.M., et al. (2014). “Hypertension education and adherence in South Africa: a cost-effectiveness analysis of community health workers”. BMC Public Health, 14: 240.

95. GBD 2015 Mortality and causes of Death Collaborators (2015). “Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015”. The Lancet, 388(10053): 1459-1544.

Có thể bạn quan tâm!

• Thuận Lợi, Khó Khăn Trong Quá Trình Can Thiệp Tại Địa Bàn Nghiên Cứu Và Tính Bền Vững Của Giải Pháp
• Thực Trạng Tăng Huyết Áp, Một Số Yếu Tố Liên Quan Ở Người 18 - 69 Tuổi Tại Một Số Phường Của Quận Thủ Đức, Thành Phố Hồ Chí Minh, Năm 2018
• Thực trạng tăng huyết áp ở người 18 - 69 tuổi tại quận Thủ Đức, thành phố Hồ Chí Minh và hiệu quả can thiệp, 2018 - 2020 - 19

Xem toàn bộ 165 trang tài liệu này.

96. Giuliano Tocci (2013). Tăng huyết áp và tổn thương cơ quan đích, Springer (Phạm Hoàng Thiên – Cập nhật kiến thức y khoa).

97. Gordon H. Williams (1998). “Hypertension vascular disease”. Harisons Principles of internnal medicine, 1380-1394.

98. Ha T.P. Do, Johanna M.G., Mai.B.Le., et al. (2015). “National prevalence and associated risk factors of hypertension and prehypertension among Vietnamese adults”. American Journal of Hypertension, 28(1): 89-96.

99. Hoang Van Minh., Peter Byass P, Dao Lan Huong., et al. (2007). “Risk Factors for Chronic Disease Among Rural Vietnamese Adults and the Association of These Factors With Sociodemographic Variables: Findings From the WHO STEPS Survey in Rural Vietnam, 2005”. Preventing Chronic diseases Journal, 4(2): A22.

100. Iskedjian M., Einarson T. R., O’Brien. B., et al. (2001). “Economic evaluation of a new acellular vaccine for pertussis in Canada”. Pharmacoeconomics, 19: 551-563.

101. Jaffe M. G., Lee G.A., Young J. D., et al. (2013). “Improved blood pressure control associated with a large-scale hypertension program”. JAMA, 310(7): 699-705.

102. Jones C., Simpson S. H., Mit chell D., et al. (2008). “Enhancing hypertension awareness and management in the elderly: lessons learned from the Airdrie Community Hypertension Awareness and Management Program (A-CHAMP)”. Canadian Journal of Cardiology, 24(7): 561-567.

103. Kaplan N. M. (2002). Measurement of blood pressure. Clinical Hypertension, Lippicott Williams and Winlkins, 25-55.

104. Khalsa T., Campbell N. R. C., Redburn., et al. (2015). “A Needs Assesssment of Sub-Sahara African National Hypertension Organizations forr Hypertension Prevention and Control Programs”. The Journal of Clinical Hypertension, 17(10): 756-757.

105. Kim N. R., Kim H. C. (2015). “Prevalence and Trends of Isolated Systolic Hypertension among Korean Adults: the Korea National Health and Nutrition Examination Survey, 1998 - 2012”. Korean Circulation Journal, 45(6): 492-499.

106. Khosravi A., Mehr G. K., Kelishadi R., et al. (2010). “The impact of a 6

- year comprehensive community trial on the awareness, treatmant and control rate of hypertension in Iran: experiences from the Isfahan healthy heart program”. BMC Cardiovasc Disord, 10: 61-62.

107. Lauzurica Z.L., Izquierdo Q.L., Vinuesa M.J., et al. (2016). “Prevalence of hypertension and associated factors in population aged 16 to 90 years old in Valencia region, Spain”. Revista Espanola de Aalud Publica, 90(1): 1-11.

108. Litzelman, D.K., Slemenda C.W., Langefeld C.D., et al. (1993). “Reduction of lower extremity clinical abnormalities in patients with

non-insulin-dependent diabetes mellitus. A randomized, controlled trial”. Ann Intern Med, 119(1): 36-41.

109. Lu C. H., Tang S. T., Lei Y. X., et al. (2015). “Community-based intervention in hypertension patients a comparison of three health education strategies”. BMC Public Health, 15(1): 33.

110. Mancia G., Fagard R., et al. (2013). “2013 ESH/ESC Guidelines for the Management of Arterial Hypertension”. European Heart Journal, 34(28): 2159-2219.

111. Mangat B. K., Campbell N., Moha S., et al. (2015). “Resources for Blood Pressure Screening Programs in Low Resource Settings: A Guide From the World Hypertension League”. The Journal of Clinical Hypertension, 17(6): 418-420.

112. Marra C., Johnston K., and Santschi V. (2017). “Costeffectiveness of pharmacist care for managing hypertension in Canada”. Canada Pharmacists Jounal, 150(3): 184-197.

113. Nguyen T.-P.-L., Wright E.P., Nguyen T.-T., et al (2016). “Cost- Effectiveness Analysis of Screening for and Managing Identified Hypertension for Cardiovascular Disease Preventionin Vietnam”. PLOS ONE journal, 11(5): 1-17.

114. Nwankwo T., Yoon S.S., Burt V. L., et al. (2013). Hypertension Among Adults in the United States: National Health and Nutrition Examination Survey, 2011 - 2012. U.S, Departement of Health and Human Services, Centers for Disease cintrol and Prevention, National Centers for Statistics.

115. Osuala Eunice O (2017). “Hypertension Prevention and Control: Effects of a Community Health Nurse-led Intervention”. J Health Educ Res Dev, 5(1): 1000210.

116. Oum S., Prak P., Khuon E., et al. (2010). Prevalence of Non- communicable Diseases Risk Factors in Cambodia, Steps Survey, Country Report, The University of Health Sciences and the Prevention Medicine Deparment of the Ministry of Health.

117. Park Y.H., Chang H.K., Kim J.S., et al. (2013). “Patient-tailored self- management intervention for older adults with hypertension in a nursing home”. Journal of Clinical Nursing, 22(5): 710-722.

118. Perez - Fernandez R., Mariđo A. F., Cadarso-Suarez C., et al. (2007). “Prevalence, awareness, treatment and control of hypertension in Galicia (Spain) and association with related diseases”. Journal of Human Hypertension, 21(5): 366-373.

119. Pimeta E., Gaddam K. K., Oparil S., et al. (2009). “Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial”. Journal of Human Hypertension, 54(3): 475-81.

120. Prevention Centers for Disease Control and. Cost-Effectiveness analysis. Access at October 20, 2021, https://www.cdc.gov/policy/polaris/econo

- economics/cost-effectiveness.html.

121. Qian Y., Zhang J., Lin Y., et al. (2009). “A Tailored Target Intervention on Influence Factors of Quality of Life in Chinese Patients with Hypertension”. Clinical and Experimental Hypertension, 32(1): 71-72.

122. Qi S. F., Zhang B., Wang H. J., et al. (2016). “Ioint effects of age and body mass index on the incidence of hypertension subtypes in the China Health and Nutrition Survey: A cohort study over 22 years”. Preventive Medicine, 89: 23-30.

123. Son P. T., Quang N. N., Viet N. L., et al. (2012). “Prevalence, awareness, treatment and control of hypertension in Vietnam-results from a national survey”, J Hum Hypertens. 26(4): 268-280.

124. Schmieder R. E., Grassi G., Kjeldsen S. E., (2013). “Patients with treatment-resistant hypertension report increased stress and anxiety: a worldwide study”. J Hypertens, 31(3): 610-615.

125. Sheldon G. S. (1999). “Overview of JNC VI: new directions in the management of hypertension and cardiovascular risk”. American Journal of Hypertension, 12(S5): 65S-75S.

126. Thankappan K. R., et al. (2013). “Impact of a community based intervention program on awareness, treatment and control of hypertension in a rural Panchayat, Kerala, India”. Indian Heart Journal, 65: 504-509.

127. The Seventh Report of the Joint National Committee on Prevention (2004). “Detection, Evaluation, and Treatment of High Blood Pressure”. NIH Publication, 11.

128. Thierry L., Chatellier G. (2001). “Prevalence, and therapeutic control of hypertension in 3000 subjects in the workplace”. Hypertension, 38: 449.

129. WHO (2005). WHO STEPS surveillance Manual: The WHO STEPwise approach to chronic disease risk factor surveillance, WHO, Geneva.

130. WHO (2007). Reducing salt intake in populations, Report of a WHO forum and technical meeting, WHO, Geneva.

131. WHO (2011). Global status report on noncommunicable diseases 2010,

WHO, Geneva.

132. WHO (2011). The WHO STEPwise approach to chronic disease risk factor surveillance (STEPS), Promotion of Fruits and Vegetables for HealthAfrican Regional, Workshop for Anglophone Countries Mount Meru Hotel, Arusha, Tanzania.

133. WHO and World Economic Forum (2011). From Burden to “Best Buys”: Reducing the Economic Impact of Non - Communicable

Diseases in Low - and Middle - Income Countries, WHO, Geneva and World Economic Forum.

134. WHO (2013). World Health Day: A global brief on hypertension: Silent killer, global public health crisis, WHO, Geneva, 1-36.

135. WHO (2013). A global brief on hypertension: Silent killer, global public health erisis: World Health Day 2013, truy cập ngày 15/9/2019 tại https://www.who.int/publications/i/item/a-global-brief-on-pertension

-silent-killer-global-public-health-crisis-world-health.

136. WHO (2014). “Global status report on noncommunicable diseases 2014: attaining the nine global noncommunicable diseases targets; a shared reponsiblity”. Journal of Human Hypertension, 27(6): 374-380.

137. Yosefy C., Ginsberg G., Viskoper R., et al. (2007). “Cost - utility analysis of a national project to reduce hypertension in Israel”. Cost Eff Resour Alloc, 5: 16-26.

138. Young J. H., Chang Y. P. C., Kim J.D.O., et al. (2005). “Differential Susceptibility to Hypertension Is Due to Selection during the Out-of- Africa Expansion”. PLOS Genetics, 1(6): 730-738.

139. Zdrojewski T., Gluszek J., Posadzy - Malaczynska A., et al. (2004). “Efects of social intervention on detection and efficacy of treatment for arterial hypertension. Main results of the Polish Four Cities Programme”. Kardiol Pol, 61(12): 546-558.